Clinical trials: Acute Cardiovascular Disease
Acute Myocardial Infarction, Congestive Heart Failure
IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction
The primary objective is to evaluate the safety and effectiveness of the IK-5001 device for the prevention of ventricular remodeling and congestive heart failure when administered to subjects who had successful percutaneous…
- Conditions
- Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction
- Trial name
- PRESERVATION-1 (NCT01226563)
- Testing
- IK-5001, Saline Solution
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 303 people
- Sponsor
- Bellerophon BCM LLC
Acute Coronary Syndrome
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).
- Trial name
- NCT00677053
- Testing
- TAK-442
- Where
- 103 sites in United States, Argentina and 17 more
- Volunteers
- 2,753 people
- Sponsor
- Takeda
Diabetic Foot Ulcer, Dehiscence of Amputation Stump
Kerecis Omega3 Wound Plus SOC vs. SOC Alone in Treating Severe Diabetic Foot Ulcers and Forefoot Amputations
This is a prospective, multi-national, multi-centre, randomized, non-blinded (photo evaluation is blinded), controlled clinical investigation in patients suffering from diabetic wounds reaching to tendon, bone, or joint.
- Conditions
- Diabetic Foot Ulcer, Dehiscence of Amputation Stump, Amputation
- Trial name
- Odinn (NCT04257370)
- Testing
- Kerecis™ Omega3 Wound, Standard of care
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Kerecis Ltd.
Acute Heart Failure, Cardiac Decompensation
Global rEgistry on decongestioN Therapy Using Less invasivE UltraFiltration
In patients with advanced volume overload, minimally invasive ultrafiltration treatment in the acute phase can have a positive effect on clinical outcome.
- Conditions
- Acute Heart Failure, Cardiac Decompensation, Volume Overload
- Trial name
- GENTLE-UF (NCT02769351)
- Testing
- periph. minimal invasive ultrafiltration
- Where
- 19 sites in Germany, Sweden and 1 more
- Volunteers
- 104 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Osteopenia, Osteoporosis
FREE Study - Fracture Reduction Evaluation
The primary objective of this study is to compare the effectiveness of standard medical therapy alone to kyphoplasty using the KyphX system for the treatment of acute vertebral body compression fractures.
- Conditions
- Osteopenia, Osteoporosis, Multiple Myeloma, Bone Neoplasms
- Trial name
- NCT00211211
- Testing
- Balloon Kyphoplasty
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Medtronic Spine LLC
Aortic Dissection
A Real-World Study on Distal Aortic Remodeling for Stanford Type B Aortic Dissection With Fabulous Thoracic Aortic Stent System
To evaluate aortic remodeling of Fabulous thoracic aortic stent system in the treatment of acute and subacute Stanford type B aortic dissection (the changes of aortic diameter, cross-sectional area,and volume of true lumen, false…
- Trial name
- NCT05883592
- Testing
- Fabulous Thoracic Aortic Stent System
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Hangzhou Endonom Medtech Co., Ltd.
Acute Coronary Syndrome
A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis
To characterize and estimate the size of different populations with a history of acute coronary syndrome in Sweden. To assess the burden of illness (co-morbidities, mortality rates healthcare resource utilization and…
- Trial name
- HELICON (NCT01984307)
- Where
- Sweden
- Volunteers
- 100,000 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Phase I Study of GW856553 (Losmapimod)
This study is the first study of losmapimod in Japanese subjects. This study will be a single-center, single blind, phase I and two part study to characterize the safety, tolerability, pharmacokinetic and pharmacodynamic profiles…
- Trial name
- NCT01648192
- Testing
- Losmapimod for single dose, Losmapimod for repeat dose
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Non-ST Elevation Myocardial Infarction
DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization
This is a prospective, randomized, double-blind, double-dummy, and controlled study of DLBS1033 in the management of acute non-ST elevation myocardial infarction (NSTEMI) without early coronary revascularization.
- Trial name
- NCT02146664
- Testing
- DLBS1033
- Where
- 2 sites in Indonesia
- Sponsor
- Dexa Medica Group
Myocardial Infarction, Acute Myocardial Infarction
Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease
The purpose of the present study is to evaluate the efficacy of the preconditioned autologous bone marrow mesenchymal stem cells for patients with ischemic heart diseases.
- Conditions
- Myocardial Infarction, Acute Myocardial Infarction, Ischemic Cardiomyopathy
- Trial name
- TPAABPIHD (NCT02504437)
- Testing
- BMMSCs
- Volunteers
- 200 people
- Sponsor
- Academy Military Medical Science, China
Myocardial Infarction, Acute, Heart Failure, Left Sided
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction…
- Trial name
- HF-REVERT (NCT05350969)
- Testing
- CDR132L
- Where
- 49 sites in Czechia, Germany and 6 more
- Volunteers
- 294 people
- Sponsor
- Cardior Pharmaceuticals GmbH
Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL)
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
The purpose of this study is to determine the dose that can be safely given to see what effect it may have on your cancer and to determine how the drug is distributed in the body.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Lymphoma, Non-Hodgkin (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
- Trial name
- NCT00710528
- Testing
- CAL-101
- Where
- 9 sites in United States
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Acute Ischemic Stroke
Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke
This is a randomized, placebo controlled, double-blind phase 3 clinical study to evaluate the efficacy and safety of transcranial ultrasound (TUS) using the Sonolysis Headframe as an adjunctive therapy to intravenous (IV) tissue…
- Trial name
- TRUST (NCT03519737)
- Testing
- tPA in combination with the Sonolysis Headframe (TUS)
- Where
- 2 sites in United States
- Volunteers
- 596 people
- Sponsor
- Cerevast Medical, Inc.
Acute Ischaemic Middle Cerebral Artery Stroke
A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke
The aim of this study was to confirm the efficacy of piracetam after 12 weeks of treatment on the aphasic status of subjects suffering from aphasia after acute ischemic middle cerebral artery stroke and having received their…
- Trial name
- NCT01883011
- Testing
- Piracetam
- Where
- 44 sites in Argentina, Austria and 13 more
- Volunteers
- 571 people
- Sponsor
- UCB S.A. - Pharma Sector
Stroke, Acute
A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
This clinical trial was planned for the purpose to re-evaluate the safety and efficacy of naloxone hydrochloride in ischemic cerebral nerve disorders caused by stroke and cerebral hemorrhage.
- Trial name
- NCT05301712
- Testing
- Naloxone hydrochloride 5.0mg/5ml, Sodium Chloride 45mg/5ml
- Where
- South Korea
- Volunteers
- 446 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
FIrst-Pass Reperfusion With the NeVa Stent-Retriever Trial
This study is designed to compare the safety, performance and efficacy of blood clot (thrombus) removal in subjects presenting with acute ischemic stroke with the NeVa versus the Solitaire stent retrievers.
- Trial name
- FIRST (NCT04072367)
- Testing
- NeVa Stent Retrievers, Solitaire Stent Retrievers
- Sponsor
- Vesalio
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Deep Vein Thrombosis Leg, DVT
ClotTriever Outcomes (CLOUT) Registry
Evaluate real world patient outcomes after treatment of acute, subacute, and chronic proximal lower extremity deep vein thrombosis (DVT) with the ClotTriever Thrombectomy System.
- Conditions
- Deep Vein Thrombosis Leg, DVT, Chronic DVT of Lower Extremity, Acute DVT of Lower Extremity
- Trial name
- CLOUT (NCT03575364)
- Testing
- ClotTriever
- Where
- 43 sites in United States
- Volunteers
- 499 people
- Sponsor
- Inari Medical
Heart Failure, Congestive
ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure
The main purpose of this study is to see if the experimental drug ZP120, when given with the approved drug furosemide to patients with acute or sub-acute heart failure, can reduce the amount of fluid in the patients' lungs and…
- Trial name
- NCT00283361
- Testing
- ZP120, I.v. catherization, 6-minutes walk performance
- Where
- 22 sites in United States
- Volunteers
- 130 people
- Sponsor
- Zealand Pharma
Treatment of Acute Coronary Syndrome (ACS).
REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
REWINDER is a multinational, multicentre, non-interventional, retrospective study of patients treated with an oral antiplatelet (ticagrelor, prasugrel or clopidogrel) while in hospital after an acute coronary syndrome (ACS)…
- Trial name
- REWINDER (NCT02190123)
- Testing
- ACS patients treated with OAP
- Where
- 15 sites in Belgium
- Volunteers
- 430 people
- Sponsor
- AstraZeneca